comparemela.com

Tc Markets Quoted News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anteris Technologies Ltd appoints highly experienced chief medical officer

The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™.

Anteri durWayne patersonHarvard school of public healthBeth israel deaconess medical centerMedicine at duke universityHarvard medical schoolMasters in public healthInterventional cardiologistAdvisory boardAnteris medical advisory boardPublic healthClinical effectivenessHarvard schoolInternal medicineSmall capsTc markets quoted

Anteris Technologies Ltd extends manufacturing agreement with LeMaitre Vascular Inc for CardioCel™ and VascuCel™

Anteris Technologies is a structural heart company delivering clinically superior and durable solutions through better science and better design.

Wayne patersonAnteri cardiocelLemaitre vascular incMaitre vascular incEuropean medical devices directorateSmall capsTc markets quotedOtcqb quotedHarma biotechAnteris technologies ltdSx avr

NA Proactive news snapshot: Australis Capital, Mountain Valley MD Holdings Inc, Kwesst Micro Systems Inc, Todos Medical Ltd, Altiplano Metals Inc, RedHill Biopharma Ltd, Naturally Splendid Enterprises Ltd, NEO Battery Materials Ltd UPDATE

A glance at some of the day s highlights from the Proactive Investors US and Canada newswires

New yorkUnited statesUnited kingdomBritish columbiaFree stateSouth africaMountain valleyEastern capeNew york stock exchangeAisédel general carlos ibáz del campoSouth dakotaWesthampton beachCambridge mineSouth africanBaran korkmazDelta indian

Amarillo Gold reports financial results as financing for Posse Project continues

Amarillo Gold Corp CEO Mike Mutchler joined Steve Darling from Proactive to share the company’s financial results for the six months ended June 30,.

Mike mutchlerAmarillo gold corpSteve darlingPosse gold projectDirector interviewsSmall capsAno capsTc markets quotedOtcqb quotedGold silverAmarillo gold corporationCve agc

Imugene Limited welcomes phase-1 trial dosing schedule for third monotherapy cohort of immunotherapy PD1-Vaxx

Clinical results continue to indicate that PD1-Vaxx is showing early signs of an immune response in patients, with antibodies to the target biomarker.

Leslie chongCohort review committeeSmall capsTc markets quotedOtcqb quotedHarma biotechImugene limitedAsx imu

vimarsana © 2020. All Rights Reserved.